Serum fibrosis markers to predict clinical and histological progression in hepatitis C non-responders

Gut

Volumn 59, Issue 10, 2010, Pages 1312-1313

  Malik, Raza ^a   Schuppan, Detlef ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; CELL PROTEIN; HYALURONIC ACID; PEGINTERFERON ALPHA2A; PROTEIN YKL 40; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG TREATMENT FAILURE; ELASTOGRAPHY; EXTRACELLULAR MATRIX; FIBROGENESIS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER FUNCTION; NOTE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BLOOD; COMPLICATION; LIVER CIRRHOSIS; PATHOLOGY; PROGNOSIS; VIROLOGY;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; PROGNOSIS;

EID: 77957193052     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.219162     Document Type: Note

References (10)

1. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838-51.
2. Friedman SL, Rockey DC, Bissell DM. Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. Hepatology 2007;45:242-9.
3. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of anti-fibrotic therapies. Hepatology 2009;50;1294-306.
4. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
5. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-18.
6. Manning DS, Afdhal NH. Diagnosis and quantification of Fibrosis. Gastroenterology 2008;134:1670-81.
7. Mayo M, Parkes J, Adams-Huet B, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008;48;1549-57.
8. Fontana RJ, Dienstag JL, Bonkovsky HL, et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010;59:1401-9.
9. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50.
10. Malik R, Afdhal N. Stiffness and Impedance: the new liver biomarkers. Clin Gastroenterol Hepatol 2007;5:1144-6.